US Pharma MarketingMerck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial
Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for a planned phase 3 study, completing the trio of contributors needed to run the colorectal cancer trial.
Source: FierceBiotech